Alexey V. Mazurov

Alexey V. Mazurov

Auto-generated profile, based on publicly available information

Alexey V. Mazurov

Russian Ministry of Health

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
AMA. V. Mazurov
A. V. Mazurov
ETE. V. Titaeva
E. V. Titaeva
SKS. G. Khaspekova
S. G. Khaspekova
ASA. N. Storojilova
A. N. Storojilova
VSV. A. Spiridonova
V. A. Spiridonova
ADA. B. Dobrovolsky
A. B. Dobrovolsky

1 July 2009 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
ADA. B. Dobrovolsky
A. B. Dobrovolsky
ETE. V. Titaeva
E. V. Titaeva
SKS. G. Khaspekova
S. G. Khaspekova
VSV. A. Spiridonova
V. A. Spiridonova
AKA. M. Kopylov
A. M. Kopylov
AMA. V. Mazurov
A. V. Mazurov

1 November 2004 in Platelets
Verified
Journal Article
Closed access
YNYa. A. Naimushin
Ya. A. Naimushin
AMA. V. Mazurov
A. V. Mazurov
In this study we investigated mechanisms of platelet interaction with von Willebrand factor (vWF) induced by activating anti-glycoprotein (GP)IIb–IIIa antibody CRC54 directed against LIBS (ligand-induced binding site epitope) in GPIIIa. It was demonstrated that aggregation of washed platelets (measured in Born aggregometer) could be stimulated by CRC54 not only in the presence of fibrinogen but vWF as well. The level of aggregation induced in the presence of saturating concentrations of vWF (∼80 μg/ml) was even higher than that in the presence of 1 mg/ml of fibrinogen. Aggregation supported by vWF unlike fibrinogen supported aggregation was almost completely inhibited not only by GPIIb–IIIa antagonists (F(ab‵)2 fragment of blocking anti-GPIIb–IIIa antibody CRC64 and peptidomimetic aggrastat) but also by anti-GPIb blocking antibody AK2. Aggregation response induced by CRC54 in the presence of vWF was much lower when normal platelets were substituted with GP-Ib-deficient platelets and this residual aggregation was not affected by anti-GPIb antibody AK2 but still inhibited by anti-GPIIb–IIIa blocking antibody fragment. CRC54-induced aggregation supported by vWF (as well as by fibrinogen) was only partially inhibited by prostaglandin E1, indicating that at least its initiation does not require activation of platelets. CRC54, both in the presence of vWF and fibrinogen, failed to stimulate serotonin secretion at physiological Ca2+ concentration of 1 mM, although substantial release reaction was detected when Ca2+ concentration was decreased to 0.1 mM. CRC54 could also stimulate platelet interaction with immobilized vWF and fibrinogen. However, unlike platelet aggregation in suspension mediated by flow phase vWF, platelet adhesion to adsorbed vWF (in a same way as to fibrinogen) was inhibited only by GPIIb–IIIa but not GPIb antagonists. The data obtained indicated that vWF support platelet aggregation induced by activating anti-GPIIb–IIIa via interaction with two receptors – activated GPIIb–IIIa and GPIb.

1 January 2002 in Platelets
Verified
Journal Article
Closed access
AMA.V. Mazurov
A.V. Mazurov
DPD.V. Pevzner
D.V. Pevzner
OAO.A. Antonova
O.A. Antonova
Tatiana V. ByzovaTatiana V. Byzova
Tatiana V. Byzova
SKS.G. Khaspekova
S.G. Khaspekova
MRM.Ya. Ruda
M.Ya. Ruda
The purpose of the study was to evaluate safety, effects on platelet aggregation and pharmacokinetics of F(ab') 2 fragments of anti-glycoprotein (GP) IIb-IIIa murine monoclonal antibody FRaMon (F(ab') 2 FRaMon) upon its intravenous administration in patients undergoing high-risk coronary angioplasty. Patients were treated before angioplasty with F(ab') 2 FRaMon at 0.2 mg/kg ( n = 17) and 0.25 mg/kg ( n = 12) bolus or with abciximab at 0.25 mg/kg bolus + 12 h infusion at 0.125 w g/kg per min ( n = 29). F(ab') 2 FRaMon at both doses decreased platelet aggregation induced by 20 w M ADP to 95, 70-80 and 40-50% of GP IIb-IIIa at 1 and 12-24 h and 3 days after injection, respectively. Thrombotic complications within the first month after angioplasty in groups treated with F(ab') 2 FRaMon and abciximab were observed in one and two patients, respectively. The data obtained have shown that F(ab') 2 FRaMon at bolus administration to patients undergoing coronary angioplasty caused no serious side effects and at comparative dosage inhibited platelet aggregation with the same efficacy as abciximab at bolus + infusion administration.

19 June 2009 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
PDF file
OAO. A. Antonova
O. A. Antonova
SLS. A. Loktionova
S. A. Loktionova
YRYu. A. Romanov
Yu. A. Romanov
OSO. N. Shustova
O. N. Shustova
MKM. V. Khachikian
M. V. Khachikian
AMA. V. Mazurov
A. V. Mazurov
Disturbances of blood flow upon vascular occlusions and spasms result in hypoxia and acidosis, while its subsequent restoration leads to reoxygenation and pH normalization (re-alkalization) in...

1 October 2007 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
OAO. A. Antonova
O. A. Antonova
SLS. A. Loktionova
S. A. Loktionova
NGN. V. Golubeva
N. V. Golubeva
YRYu. A. Romanov
Yu. A. Romanov
AMA. V. Mazurov
A. V. Mazurov